Kidney Tumor Classification via DNA Methylation Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging techniques fail to definitively distinguish between benign and malignant kidney tumors, leading to over-diagnosis and over-treatment of indolent lesions, as they rely on radiographic features that are not specific enough to identify malignant lesions requiring early intervention.
Innovation Solution
A method involving DNA methylation analysis using specific biomarkers to classify kidney tumors by determining the methylation status of DNA from biopsy samples, including liquid biopsies, and comparing it to selected methylated biomarkers to differentiate between clear cell malignant, papillary malignant, chromophobe malignant, angiomylolipomas, and oncocytoma benign types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Difficulty of detecting and measuring
If radiologic imaging is used to evaluate kidney tumors, then detection sensitivity is improved, but diagnostic accuracy deteriorates due to non-specific radiographic features
Solution Approach 1:
The patent introduces DNA methylation markers as an intermediary between radiologic imaging and final diagnosis. These molecular markers serve as a mediator that provides specific biochemical information to complement non-specific radiographic features, thereby improving diagnostic accuracy while maintaining high detection sensitivity
Solution Approach 2:
The patent combines multiple diagnostic approaches (radiologic imaging features plus DNA methylation profile analysis) into a composite diagnostic system. This composite approach integrates structural imaging data with molecular biomarker data to achieve both high sensitivity and high diagnostic accuracy
2Quantity of substance
If needle biopsy is used to evaluate small renal masses, then tissue sampling is obtained, but diagnostic accuracy deteriorates due to low sensitivity and high false negativity rate
Solution Approach 1:
The patent changes the analytical parameters by shifting from histological evaluation to DNA methylation profile analysis. This parameter change allows for more sensitive detection of malignant transformations in small renal masses, improving diagnostic accuracy while working with the limited tissue samples obtained via needle biopsy
Solution Approach 2:
The patent replaces the mechanical/histological evaluation system with a molecular biology-based system. Instead of relying on pathologist visualization of tissue architecture, the system uses PCR-based detection of DNA methylation patterns, which provides higher sensitivity and accuracy for detecting malignancy in small samples
3Reliability
If mRNA and protein-based markers are used in needle biopsy, then sensitivity may be improved, but device complexity and cost increase due to sample stability issues and analysis requirements
Solution Approach 1:
The patent employs DNA methylation markers that are stable, easy to extract, and analyze using relatively simple and inexpensive PCR-based methods. These markers serve as practical, robust alternatives to fragile mRNA and protein markers, maintaining high sensitivity while reducing analytical complexity and cost
Solution Approach 2:
The patent extracts and analyzes specific DNA methylation patterns from needle biopsy samples. By focusing on these stable epigenetic modifications rather than attempting to preserve and analyze labile mRNA or proteins, the method simplifies the analytical process while maintaining high diagnostic sensitivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves the accuracy of needle biopsies in distinguishing between benign and malignant lesions, reducing unnecessary treatments by providing subtype-specific renal cancer biomarkers for improved clinical management and minimizing patient morbidity.
Implementation Method 1
DNA methylation alterations are among the first changes to occur in the process of tumorigenesis. Because of this, it is likely that they will be present in the majority of tumors, as well as in less aggressive malignancies. Furthermore, they are easily detected in needle biopsy samples.
Data Source
AI summary
A method of classifying kidney tumors is provided. The method includes obtaining a sample from a subject, isolating DNA from the sample, determining the methylation status of the DNA, and comparing the methylation status of the DNA to one or more methylated biomarkers selected from the following: cg04877910, cg09667289, cg05274650, cg11473616, cg16935734, cg27534624, cg21851713, cg15867829, cg15679829, cg08884979, cg09538401, cg26811868, cg05367028, cg19816080, cg20108357, cg25504868, cg11201447, cg19922137, cg14706317, cg15902830, cg10794973, cg10777887, cg03290131, cg07851269, cg11264947, cg00279406, cg23140965, cg03574652, cg03265671, cg24864241, cg01572891, cg00193963, cg14329285, cg17819990, cg17298239, cg23856138, cg21049501, cg11808936, cg25170591, cg17983632, cg08141142, cg19848599, cg25799109, cg07093324, cg16223546, cg07604732, cg12149606, cg08949329, cg27166177, cg26177041, cg09885851, cg22876153, cg21386992, cg02309772, cg02833180, cg20007890, cg04972244, cg02666955 and cg12102682. The comparison indicates whether the sample is clear cell malignant, papillary malignant, chromophobe malignant, angiomylolipomas (AML) benign, or oncocytoma benign.